Member Info for Krone

The Bio-Europe conference next week will provide a high profile backdrop against which to release news.

RMM - absolutely and the key thing is not to miss the unique opportunity that the grant/partnering with big pharma will offer for Sareum to really present a really upbeat message. This is not ramping just expressing confidence in the smorgasbord of the delectable goodies that Sareum has to offer.

An interesting and current read.
https://www.nature.com/articles/s41573-020-0082-8

Possibly an FT occk up then.

FT indicating that First Pacific have sold their 62.5m holding.....so we appear to have lost the sole institutional investor which is surprising given the current state of play with positive news expected on numerous fronts.
https://markets.ft.com/data/equities/tearsheet/profile?s=SAR:LSE

Hi Num4 - done.

Not sure of the relevance of this, if any?
ESPO update refers to the 'Lapse of the patent in a contracting state New state(s): LT, NO'
https://register.epo.org/application?number=EP16150956&tab=main

Num4 - excellent post, thank you.

Eli Lilly's [JAK1/JAK2i] Olumiant pares COVID-19 patients' recovery time down to 7 days as an add-on to remdesivir fiercepharma.com/pharma/eli-lil…
Sareum $SAR.L #TYK2 #AIM #biotech
https://twitter.com/sareumplc/status/1317095991531704321?s=21
It wouldn’t be ramping to add something along the lines...’Sareum’s TYK2/Jak1 showing great promise without the toxicity issues’

Thanks Basser

Actual comment from the bod.... a rare thing indeed and perhaps a clue?
“Good set of results today for @Sareumplc. Particularly pleased with the formulation progress with SDC-1801!”
https://twitter.com/sparksinsurrey/status/1316001539425796099?s=21

HI Potnak - the grant award will confirm which partner organisations are involved. Given the enormity of the Covid crisis it is reasonable to suppose that Tim et al will have been given an early heads up on the approval of the grant application/s and that the planning of the pre-clinical work is already well underway. Once confirmed this will be taken forward at warp factor 10, subject of course to the appropriate checks and balances which are the hallmark of Sareum.

https://www.sec.gov/Archives/edgar/data/1290149/000119312516765907/d255357dex101.htm

Apols, disregard previous posts.

This relates to the double-patenting issue so presumably 1801?

Apologies if previously posted.
Further details of the patent allowance now on the USPTO website.
https://register.epo.org/documentView?number=US.201916351620.A&documentId=1-12-US++163516200GP1+

ADVFN

Currently up 19.4% on larger volume...

(JAK1/JAK2i) Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen $LLY $INCY newsfilter.io/a/1bfc907a5e25…
Sareum $SAR.L #TYK2 #AIM #biotech

https://twitter.com/sareumplc/status/1314231170264174593?s=21

Cambridge drug development business Sareum Holdings plc saw its share price rise more than 13 per cent in the UK after receiving a patent boost in the US.
The AIM-quoted company is delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases.
In a genuine breakthrough development, Sareum reveals that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme.
This programme is in preclinical development and targets cancer and cancer immunotherapy. The patent will protect the SDC-1802 molecule and pharmaceutical preparations arising from the research.
Subject to certain formalities being completed, the company expects that the patent will be granted within three months.T his will complete the patent protection for this programme across all major territories.
The landmark follows similar patent protection being granted to the company in Europe, Japan and China.
Sareum’s CSO Dr John Reader said: “The granting of this patent in the US will complete the protection of the intellectual property for our proprietary SDC-1802 Programme across all major markets.
“The board believes that the patent will enhance the value of its TYK2/JAK1 inhibitor programmes and the company’s negotiating position as it continues to engage in discussions with potential licence partners.”
https://www.businessweekly.co.uk/news/biomedtech/us-patent-breakthrough-sareum